Related Experiment Video

Updated: Sep 14, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.9K

Decoding subclonal anti-tumor immunity

Jason E Chan1, Tuomas Tammela2

  • 1Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Cancer Cell
|July 18, 2025
PubMed

Insights

Tumors evolve to evade immune detection. This study profiles tumor subclone immune escape using patient tumor and immune cell co-cultures, revealing cancer-intrinsic mechanisms.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Biology

Background:

  • Tumorigenesis involves subclonal evolution, where distinct cancer cell populations emerge within a tumor.
  • Cancer cells can develop mechanisms to evade the host immune system, contributing to disease progression and treatment resistance.

Purpose of the Study:

  • To functionally profile immune escape mechanisms at the single-subclone level.
  • To investigate cancer-intrinsic mechanisms of immune evasion.
  • To establish a co-culture platform for interrogating tumor-immune cell interactions.

Main Methods:

  • Utilized the TRACERx cohort for patient-derived tumor samples.
  • Developed co-culture systems with autologous tumor and immune cells.
  • Applied single-clone resolution techniques to assess immune interactions.

Main Results:

  • Identified distinct immune escape phenotypes among tumor subclones.
  • Demonstrated the capacity of specific tumor subclones to resist immune surveillance.
  • Validated the co-culture platform for dissecting tumor-immune interactions.

Conclusions:

  • Subclonal evolution directly contributes to immune evasion in cancer.
  • Cancer-intrinsic mechanisms drive tumor immune escape.
  • Co-culture platforms offer a powerful tool for studying tumor-immune interactions and developing targeted therapies.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.8K
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.3K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
5.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.2K